Recent reports on Altria Group project a mixed bag concerning its performance in the bio-tech market. Despite underperforming compared to competitors on several occasions, the group has enjoyed moments of out-performance. Respected figures within the financial market have recommended buying Altria, although calls for selling have also emerged. Institutional ownership stands strong at 62%, which is a positive indicator of Altria's perception among investment experts. Dividend strengths continue to appeal to current and potential investors despite the slight declines in revenues. Some draws for Altria include a long dividend streak and a yield reaching 8.6%. The company also recently announced a $1 billion buyback and continues to meet EPS successfully. However, caution is likewise advised: some analysts question the sustainability of the business model, and despite successes, the stock continues to sporadically underperform. Current shareholder Panagora Asset Management has beefed up its stake by acquiring extra shares. Finally, the group continues to have a strong trading presence, delivering in-line earnings several days in a row.
Altria Group MO News Analytics from Mon, 09 Oct 2023 07:00:00 GMT to Thu, 23 May 2024 13:45:00 GMT - Rating 0 - Innovation 5 - Information 7 - Rumor -6
